Bristol-Myers Squibb Company – Product Pipeline Review

Global Markets Direct’s, ‘Bristol-Myers Squibb Company – Product Pipeline Review – 2016’, provides an overview of the Bristol-Myers Squibb Company’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Bristol-Myers Squibb Company, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Bristol-Myers Squibb Company

The report provides overview of Bristol-Myers Squibb Company including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Bristol-Myers Squibb Company’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Bristol-Myers Squibb Company’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Bristol-Myers Squibb Company’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Bristol-Myers Squibb Company

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Bristol-Myers Squibb Company’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Bristol-Myers Squibb Company Snapshot 7

Bristol-Myers Squibb Company Overview 7

Key Information 7

Key Facts 7

Bristol-Myers Squibb Company - Research and Development Overview 8

Key Therapeutic Areas 8

Bristol-Myers Squibb Company - Pipeline Review 18

Pipeline Products by Stage of Development 18

Pipeline Products - Monotherapy 19

Pipeline Products - Combination Treatment Modalities 20

Pipeline Products - Partnered Products 21

Pipeline Products - Out-Licensed Products 23

Bristol-Myers Squibb Company - Pipeline Products Glance 25

Bristol-Myers Squibb Company - Late Stage Pipeline Products 25

Bristol-Myers Squibb Company - Clinical Stage Pipeline Products 28

Bristol-Myers Squibb Company - Early Stage Pipeline Products 33

Bristol-Myers Squibb Company - Drug Profiles 37

nivolumab 37

daclatasvir dihydrochloride + asunaprevir 45

abatacept 47

apixaban 50

beclabuvir hydrochloride 52

brivanib alaninate 54

ipilimumab 57

ulocuplumab 62

BMS-394136 64

BMS-754807 65

BMS-833923 67

BMS-919373 69

BMS-986020 70

BMS-986036 71

BMS-986142 73

CXL-1427 74

dasatinib 75

lirilumab 78

lulizumab pegol 80

Recombinant Protein to Antagonize Fibroblast Growth Factor Receptor for Fibrosis 81

urelumab 82

BMS-986004 84

BMS-986012 85

BMS-986016 86

BMS-986089 87

BMS-986148 88

BMS-986156 89

BMS-986158 90

TD-139 91

Antibody to Target CD40 Ligand for Immunology 93

Biologic to Inhibit PD-L1 for Immunology 94

BMS-262084 95

BMS-777607 96

BMS-813160 98

BMS-906024 99

BMS-963272 101

BMS-986090 102

BMS-986104 103

BMS-986115 104

BMS-986120 105

BMS-986141 106

BMS-986147 107

BMS-986165 108

BMS-986168 109

BMS-986171 110

BMS-986186 111

FLX-925 112

KOS-1803 113

Recombinant Protein 1 to Antagonize Fibroblast Growth Factor Receptor for Fibrosis 115

Small Molecule for Oncology 116

Small Molecule to Antagonize PAR4 for Thromboembolic Disorders 117

Small Molecule to Inhibit BTK for Immunology 118

Small Molecule to Inhibit MGAT2 for Type 2 Diabetes and Obesity 119

Small Molecule to Inhibit TYK2 for Immunology 120

BMS-817378 121

ALB-109780 122

AMR-2 123

ARX-720 125

BMS-457 126

BMS-593214 127

BMS-654457 128

BMS-751324 129

BMS-795311 130

BMS-816106 131

BMS-869780 132

BMS-871 133

BMS-884775 134

BMS-986177 135

BMS-986195 136

BMS-986205 137

CXL-1036 138

Drug for Metabolic Disorders 139

Drugs to Agonize FPR-2 for Inflammation 140

DT-1154 141

F-001287 142

NP-11948 143

Small Molecule 2 to Inhibit Factor XIa for Thrombosis 144

Small Molecule for Pulmonary Arterial Hypertension 145

Small Molecule to Activate Kv7.2 for Neuropathic Pain and Diabetic Neuropathy 146

Small Molecule to Antagonize Neuropeptide Y Receptor Y1 for Obesity 147

Small Molecule to Antagonize NK1R and Block SERT for Depression 148

Small Molecule to Inhibit IAP for Melanoma 149

Small Molecule to Inhibit NS5B for Hepatitis C 150

Small Molecule to Inhibit XIAP and c-IAP for Melanoma 151

Small Molecules to Inhibit Beta Secretase 1 for Alzheimer's Disease 152

Small Molecules to Inhibit ROR-Gamma for Inflammation 153

Monoclonal Antibody Conjugates for Oncology 154

Proteins for Immunology and Oncology 155

Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia 156

Small Molecules to Antagonize Calcitonin Gene-Related Peptide for Migraine 157

Small Molecules to Antagonize CCR2 158

Small Molecules to Inhibit IDO and TDO for Oncology 159

Small Molecules to Inhibit IDO for Oncology 160

Small Molecules to Inhibit JAK 3 for Inflammation and Autoimmune Diseases 161

Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders 162

Small Molecules to Inhibit TDO for Oncology 163

Bristol-Myers Squibb Company - Pipeline Analysis 164

Bristol-Myers Squibb Company - Pipeline Products by Target 164

Bristol-Myers Squibb Company - Pipeline Products by Route of Administration 174

Bristol-Myers Squibb Company - Pipeline Products by Molecule Type 175

Bristol-Myers Squibb Company - Pipeline Products by Mechanism of Action 176

Bristol-Myers Squibb Company - Recent Pipeline Updates 183

Bristol-Myers Squibb Company - Dormant Projects 226

Bristol-Myers Squibb Company - Dormant Projects 226

Bristol-Myers Squibb Company - Discontinued Pipeline Products 231

Bristol-Myers Squibb Company - Discontinued Pipeline Products 231

Discontinued Pipeline Product Profiles 232

Bristol-Myers Squibb Company - Company Statement 237

Bristol-Myers Squibb Company - Locations And Subsidiaries 239

Head Office 239

Other Locations & Subsidiaries 239

Bristol-Myers Squibb Company - Key Manufacturing Facilities 246

Appendix 247

Methodology 247

Coverage 247

Secondary Research 247

Primary Research 247

Expert Panel Validation 247

Contact Us 247

Disclaimer 248

List of Tables

List of Tables

Bristol-Myers Squibb Company, Key Information 14

Bristol-Myers Squibb Company, Key Facts 14

Bristol-Myers Squibb Company – Pipeline by Indication, 2016 16

Bristol-Myers Squibb Company – Pipeline by Stage of Development, 2016 25

Bristol-Myers Squibb Company – Monotherapy Products in Pipeline, 2016 26

Bristol-Myers Squibb Company – Combination Treatment Modalities in Pipeline, 2016 27

Bristol-Myers Squibb Company – Partnered Products in Pipeline, 2016 28

Bristol-Myers Squibb Company – Partnered Products/ Combination Treatment Modalities, 2016 29

Bristol-Myers Squibb Company – Out-Licensed Products in Pipeline, 2016 30

Bristol-Myers Squibb Company – Out-Licensed Products/ Combination Treatment Modalities, 2016 31

Bristol-Myers Squibb Company – Pre-Registration, 2016 32

Bristol-Myers Squibb Company – Filing rejected/Withdrawn, 2016 33

Bristol-Myers Squibb Company – Phase III, 2016 34

Bristol-Myers Squibb Company – Phase II, 2016 35

Bristol-Myers Squibb Company – Phase I, 2016 37

Bristol-Myers Squibb Company – IND/CTA Filed, 2016 40

Bristol-Myers Squibb Company – Preclinical, 2016 41

Bristol-Myers Squibb Company – Discovery, 2016 43

Bristol-Myers Squibb Company – Pipeline by Target, 2016 171

Bristol-Myers Squibb Company – Pipeline by Route of Administration, 2016 181

Bristol-Myers Squibb Company – Pipeline by Molecule Type, 2016 182

Bristol-Myers Squibb Company – Pipeline Products by Mechanism of Action, 2016 183

Bristol-Myers Squibb Company – Recent Pipeline Updates, 2016 190

Bristol-Myers Squibb Company – Dormant Developmental Projects,2016 233

Bristol-Myers Squibb Company – Discontinued Pipeline Products, 2016 238

Bristol-Myers Squibb Company, Other Locations 246

Bristol-Myers Squibb Company, Subsidiaries 246

Bristol-Myers Squibb Company, Key Manufacturing Facilities 253

List of Figures

List of Figures

Bristol-Myers Squibb Company – Pipeline by Top 10 Indication, 2016 16

Bristol-Myers Squibb Company – Pipeline by Stage of Development, 2016 25

Bristol-Myers Squibb Company – Monotherapy Products in Pipeline, 2016 26

Bristol-Myers Squibb Company – Combination Treatment Modalities in Pipeline, 2016 27

Bristol-Myers Squibb Company – Partnered Products in Pipeline, 2016 28

Bristol-Myers Squibb Company – Out-Licensed Products in Pipeline, 2016 30

Bristol-Myers Squibb Company – Pipeline by Top 10 Target, 2016 171

Bristol-Myers Squibb Company – Pipeline by Route of Administration, 2016 181

Bristol-Myers Squibb Company – Pipeline by Molecule Type, 2016 182

Bristol-Myers Squibb Company – Pipeline Products by Top 10 Mechanism of Action, 2016 183

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports